Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 27.252
Filtrer
1.
Acta Neurobiol Exp (Wars) ; 84(2): 180-190, 2024 Jun 28.
Article de Anglais | MEDLINE | ID: mdl-39087841

RÉSUMÉ

Cannabinoid and serotonin systems regulate many biological processes. The aim of the present study was to investigate the functional interaction between the cannabinoid and serotonergic systems of the primary somatosensory region (S1) of the brain in epileptiform activity caused by penicillin. The ACEA (an agonist of CB1 receptor), AM­251 (an antagonist of CB1 receptor), 8­OH­DPAT (an agonist of 5­HT1A receptor) and WAY­100635 (an antagonist of 5­HT1A receptor) were administered into the S1 after the same site administration of penicillin in urethane­anesthetized rats. Electrocorticographic recording was done for a 90­min period. The spike waves number and amplitude were recorded in 15­min intervals. Areas under the curve (AUC) of the above­mentioned spike alterations was calculated in 90 min. Spike waves with frequency of 30/min and amplitude of 1.3 mV were appeared after penicillin microinjection. The ACEA (50 ng), 8­OH­DPAT (500 ng) and ACEA (10 ng) plus 8­OH­DPAT (100 ng) reduced epileptiform activity. The AM­251 (50 ng) and WAY­100365 (500 ng) prevented the reducing effects of ACEA (50 ng) and 8­OH­DPAT (500 ng). The AM­251 alone increased spike waves frequency. The AUC results supported the effects of the above­mentioned treatments. The results showed that activating CB1 and 5­HT1A receptors in the S1 may reduce the epileptiform activity caused by penicillin. Therefore, alone and together activation of central CB1 and 5­HT1A receptors might be considered in the management of epilepsy treatment.


Sujet(s)
Modèles animaux de maladie humaine , Épilepsie , Pénicillines , Rat Wistar , Récepteur cannabinoïde de type CB1 , Récepteur de la sérotonine de type 5-HT1A , Cortex somatosensoriel , Animaux , Cortex somatosensoriel/effets des médicaments et des substances chimiques , Cortex somatosensoriel/métabolisme , Récepteur de la sérotonine de type 5-HT1A/métabolisme , Pénicillines/pharmacologie , Récepteur cannabinoïde de type CB1/métabolisme , Récepteur cannabinoïde de type CB1/agonistes , Mâle , Épilepsie/induit chimiquement , Épilepsie/métabolisme , Épilepsie/traitement médicamenteux , Rats , Acides arachidoniques/pharmacologie , 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol/pharmacologie , Pyridines/pharmacologie , Pipérazines/pharmacologie , Électrocorticographie , Pipéridines/pharmacologie , Électroencéphalographie/méthodes , Pyrazoles
2.
Sex Health ; 212024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39008622

RÉSUMÉ

Background Gonorrhoea notifications have increased substantially in Australia over the past decade. Neisseria gonorrhoeae is already highly resistant to several antibiotics and so, alternatives to first-line treatment are generally strongly discouraged. The penicillin allergy label (AL) on patient medical records has previously been shown to influence prescribing practices, to the detriment of best-practice management and antimicrobial stewardship. This study aimed to understand how the penicillin AL influences antibiotic selection for gonorrhoea treatment at Canberra Sexual Health Centre. Methods A retrospective chart audit of gonorrhoea cases treated at Canberra Sexual Health Centre between January 2020 and October 2023 (n =619 patients, n =728 cases). Antibiotic selection was assessed according to penicillin AL status. Ceftriaxone selection was assessed according to penicillin allergy severity reported in the medical records and as determined using a validated antibiotic allergy assessment tool. Results Cases with a penicillin AL were more likely to receive antibiotics other than ceftriaxone (n =7/41, 17.1%) than cases without the label (n =8/687, 1.2%, P n =28/41, 68.3%) to apply the assessment tool. Those reported as low-severity in the records were more likely to receive ceftriaxone (n =21/22, 95.5%) than those reported as moderate-high (n =7/11, 63.6%) or unreported (n =6/8, 0.75%). Conclusions Treatment of gonorrhoea in outpatient settings requires an understanding of penicillin allergy, and the ability to quickly and accurately identify penicillin-AL patients who can safely tolerate ceftriaxone. Institutionally endorsed penicillin allergy de-labelling protocols and access to easy-to-navigate prescribing advice within national sexually transmitted infection management guidelines would support this.


Sujet(s)
Antibactériens , Ceftriaxone , Hypersensibilité médicamenteuse , Gonorrhée , Pénicillines , Humains , Gonorrhée/traitement médicamenteux , Ceftriaxone/usage thérapeutique , Études rétrospectives , Antibactériens/usage thérapeutique , Pénicillines/usage thérapeutique , Pénicillines/effets indésirables , Femelle , Mâle , Adulte , Neisseria gonorrhoeae , Australie , Dossiers médicaux , Types de pratiques des médecins/statistiques et données numériques , Adulte d'âge moyen , Étiquetage de médicament
4.
Article de Russe | MEDLINE | ID: mdl-39003557

RÉSUMÉ

The article considers on the basis of analysis of archival documents issue of rendering assistance by the Soviet Union to the countries of Eastern Europe to organize production of penicillin. It is established that by the mid of 1950s, modern powerful plants were launched in Bulgaria, Romania and Czechoslovakia by the forces of Soviet engineers . Their construction was carried out on preferential terms for countries-customers. The mutually beneficial cooperation in sphere of production of antibiotics carried out and with other countries of this region. It is demonstrated that the USSR, performing task of enormous humanitarian significance in conditions of the Cold War, simultaneously implemented another goal - formation of loyalty of population of these countries and organization of coalition of friendly states on its Western borders.


Sujet(s)
Pénicillines , Humains , URSS , Histoire du 20ème siècle , Pénicillines/histoire , Europe de l'Est , Industrie pharmaceutique/histoire , Industrie pharmaceutique/organisation et administration , Antibactériens/histoire
6.
Nature ; 631(8020): 386-392, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38961295

RÉSUMÉ

Streptococcus pneumoniae is a leading cause of pneumonia and meningitis worldwide. Many different serotypes co-circulate endemically in any one location1,2. The extent and mechanisms of spread and vaccine-driven changes in fitness and antimicrobial resistance remain largely unquantified. Here using geolocated genome sequences from South Africa (n = 6,910, collected from 2000 to 2014), we developed models to reconstruct spread, pairing detailed human mobility data and genomic data. Separately, we estimated the population-level changes in fitness of strains that are included (vaccine type (VT)) and not included (non-vaccine type (NVT)) in pneumococcal conjugate vaccines, first implemented in South Africa in 2009. Differences in strain fitness between those that are and are not resistant to penicillin were also evaluated. We found that pneumococci only become homogenously mixed across South Africa after 50 years of transmission, with the slow spread driven by the focal nature of human mobility. Furthermore, in the years following vaccine implementation, the relative fitness of NVT compared with VT strains increased (relative risk of 1.68; 95% confidence interval of 1.59-1.77), with an increasing proportion of these NVT strains becoming resistant to penicillin. Our findings point to highly entrenched, slow transmission and indicate that initial vaccine-linked decreases in antimicrobial resistance may be transient.


Sujet(s)
Aptitude génétique , Cartographie géographique , Streptococcus pneumoniae , Humains , Aptitude génétique/effets des médicaments et des substances chimiques , Aptitude génétique/génétique , Génome bactérien/génétique , Résistance aux pénicillines/effets des médicaments et des substances chimiques , Résistance aux pénicillines/génétique , Pénicillines/pharmacologie , Infections à pneumocoques/épidémiologie , Infections à pneumocoques/immunologie , Infections à pneumocoques/microbiologie , Infections à pneumocoques/transmission , Vaccins antipneumococciques/immunologie , Sérogroupe , République d'Afrique du Sud/épidémiologie , Streptococcus pneumoniae/effets des médicaments et des substances chimiques , Streptococcus pneumoniae/génétique , Streptococcus pneumoniae/immunologie , Streptococcus pneumoniae/isolement et purification , Vaccins conjugués/immunologie , Vaccin antipneumococcique conjugué heptavalent/immunologie , Locomotion
7.
Int J Mol Sci ; 25(14)2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39062934

RÉSUMÉ

Serine ß-lactamase TEM-1 is the first ß-lactamase discovered and is still common in Gram-negative pathogens resistant to ß-lactam antibiotics. It hydrolyzes penicillins and cephalosporins of early generations. Some of the emerging TEM-1 variants with one or several amino acid substitutions have even broader substrate specificity and resistance to known covalent inhibitors. Key amino acid substitutions affect catalytic properties of the enzyme, and secondary mutations accompany them. The occurrence of the secondary mutation M182T, called a "global suppressor", has almost doubled over the last decade. Therefore, we performed saturating mutagenesis at position 182 of TEM-1 to determine the influence of this single amino acid substitution on the catalytic properties, thermal stability, and ability for thermoreactivation. Steady-state parameters for penicillin, cephalothin, and ceftazidime are similar for all TEM-1 M182X variants, whereas melting temperature and ability to reactivate after incubation at a higher temperature vary significantly. The effects are multidirectional and depend on the particular amino acid at position 182. The M182E variant of ß-lactamase TEM-1 demonstrates the highest residual enzymatic activity, which is 1.5 times higher than for the wild-type enzyme. The 3D structure of the side chain of residue 182 is of particular importance as observed from the comparison of the M182I and M182L variants of TEM-1. Both of these amino acid residues have hydrophobic side chains of similar size, but their residual activity differs by three-fold. Molecular dynamic simulations add a mechanistic explanation for this phenomenon. The important structural element is the V159-R65-E177 triad that exists due to both electrostatic and hydrophobic interactions. Amino acid substitutions that disturb this triad lead to a decrease in the ability of the ß-lactamase to be reactivated.


Sujet(s)
Substitution d'acide aminé , Stabilité enzymatique , bêta-Lactamases , bêta-Lactamases/composition chimique , bêta-Lactamases/génétique , bêta-Lactamases/métabolisme , Méthionine/composition chimique , Méthionine/métabolisme , Méthionine/génétique , Modèles moléculaires , Mutagenèse , Cinétique , Simulation de dynamique moléculaire , Pénicillines/composition chimique , Pénicillines/métabolisme
8.
J Med Libr Assoc ; 112(1): 55-59, 2024 Jan 16.
Article de Anglais | MEDLINE | ID: mdl-38911526

RÉSUMÉ

In 1928, Alexander Fleming (1881-1955) identified penicillin, the world's first antibiotic. It was a chance discovery that could have easily been missed had Fleming not taken a second look at a contaminated Petri dish. The discovery of penicillin marked a profound turning point in history as it was the first time deadly infections such as bacterial pneumonia, sepsis, diphtheria, meningitis, and puerperal fever after childbirth could be cured, and it paved the way for the development of additional antibiotics. The Alexander Fleming Laboratory Museum, one of several London Museums of Health and Medicine, is a reconstruction of Fleming's laboratory in its original location at St. Mary's Hospital. As if stepping back in time, visitors gain a glimpse into the man, his bacteriology work, and the events surrounding this important finding. For those unable to travel to London, this article provides a brief narrative of the fascinating story.


Sujet(s)
Pénicillines , Histoire du 20ème siècle , Humains , Pénicillines/histoire , Histoire du 19ème siècle , Antibactériens/histoire , Antibactériens/usage thérapeutique , Londres
9.
PLoS One ; 19(6): e0303271, 2024.
Article de Anglais | MEDLINE | ID: mdl-38924011

RÉSUMÉ

Antibiotic persistence is a phenomenon, where a small fraction of a bacterial population expresses a phenotypic variation that allows them to survive antibiotic treatment, which is lethal to the rest of the population. These cells are called persisters cells, and their occurrence has been associated with recurrent disease. Streptococcus agalactiae is a human pathobiont, able to cause invasive infections, and recurrent infections have been reported to occur in both newborns and adults. In this study, we demonstrated that S. agalactiae NEM316 can form persister cells when exposed to antibiotics from different classes. The frequency of persister cell formation was dependent on bacterial growth phase and the class of antibiotics. The ability to form persister cells in response to penicillin was shown to be a general trait among different clinical S. agalactiae isolates, independent of sero- and sequence-type. Taken together, this study shows the existence of antibiotic tolerant S. agalactiae persister cells, which may explain why this bacterial species frequently persists after treatment of invasive infection and can be associated with recurrent disease.


Sujet(s)
Antibactériens , Tests de sensibilité microbienne , Streptococcus agalactiae , Streptococcus agalactiae/effets des médicaments et des substances chimiques , Antibactériens/pharmacologie , Humains , Infections à streptocoques/microbiologie , Infections à streptocoques/traitement médicamenteux , Résistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Pénicillines/pharmacologie
10.
Arch Dermatol Res ; 316(7): 363, 2024 Jun 08.
Article de Anglais | MEDLINE | ID: mdl-38850287

RÉSUMÉ

Streptococcal infections may contribute to psoriasis development, and antistreptococcal treatments are considered potential therapies, but their effectiveness remains uncertain due to limited systematic evidence. Our objective was to analyze antistreptococcal therapies' effectiveness in improving psoriasis. We conducted a systematic review following PRISMA guidelines, evaluating antistreptococcal treatment efficacy in psoriasis patients from PubMed, Scopus, and Embase databases until August 14, 2022. Eligible studies included psoriasis patients undergoing antistreptococcal therapy, regardless of demographics or psoriasis type. 50 studies (1778 patients) were analyzed, with penicillins/aminopenicillins as the most studied antibiotics (21 studies), showing mixed outcomes, some reporting significant improvement in guttate psoriasis, while others showed no significant difference. Rifampin demonstrated positive results in most of ten studies, and macrolides showed varying effectiveness in two studies. Tonsillectomy in 14 studies (409 patients) mainly focusing on guttate and chronic plaque psoriasis showed positive outcomes, indicating improved symptoms and quality of life. Limitations include heterogeneous studies, sampling bias, and quality of evidence. This systematic review reveals limited and varied evidence for systemic antibiotic therapy efficacy in psoriasis treatment, while tonsillectomy emerges as a potentially beneficial antistreptococcal option, urging further well-designed, controlled studies with larger sample sizes and standardized protocols for better comparisons.


Sujet(s)
Antibactériens , Psoriasis , Infections à streptocoques , Humains , Psoriasis/traitement médicamenteux , Antibactériens/usage thérapeutique , Infections à streptocoques/traitement médicamenteux , Résultat thérapeutique , Qualité de vie , Pénicillines/usage thérapeutique , Rifampicine/usage thérapeutique
11.
Food Chem ; 456: 139946, 2024 Oct 30.
Article de Anglais | MEDLINE | ID: mdl-38852450

RÉSUMÉ

To effectively monitor multi-residues of penicillin antibiotics (PENs) in milk, we developed a novel ratiometric electrochemical aptasensor enabling simultaneous detection of PENs. The aptasensor employed a broad-spectrum aptamer as a recognition element, niobium carbide functionalized with methylene blue (Nb2C-MB) as a reference signal generator, and a ferrocene-labeled aptamer (Fc-Apt) as an output signal. Electrodes were modified with Fe-N-C doped carbon nanotubes (Fe-N-C-CNTs) to amplify detection signals further. During detection, Fc-Apt binding to PENs decreased Fc current intensity (IFc) and increased MB current intensity (IMB). The simultaneous detection of PENs was achieved using IMB/IFc as a quantitative signal. Under optimal conditions, a good linear relationship between IMB/IFc and antibiotic concentration was observed, indicating the aptasensor had a robustness. The limits of detection of aptasensor for four penicillin antibiotics and their mixed targets were 0.093-0.191 nM. This work provides a new approach to multi-residue detection of the same class of antibiotics.


Sujet(s)
Antibactériens , Aptamères nucléotidiques , Techniques de biocapteur , Techniques électrochimiques , Contamination des aliments , Lait , Pénicillines , Lait/composition chimique , Aptamères nucléotidiques/composition chimique , Animaux , Antibactériens/analyse , Antibactériens/composition chimique , Pénicillines/analyse , Pénicillines/composition chimique , Contamination des aliments/analyse , Limite de détection , Résidus de médicaments/analyse , Résidus de médicaments/composition chimique , Bovins
12.
Inorg Chem ; 63(27): 12593-12603, 2024 Jul 08.
Article de Anglais | MEDLINE | ID: mdl-38923955

RÉSUMÉ

Procedures for the preparation of transition metal complexes having intact bicyclic cepham or penam systems as ligands have been developed. Starting from readily available 4-azido-2-azetidinones, a synthetic approach has been tuned using a copper-catalyzed azide-alkyne cycloaddition between 3-azido-2-azetinones and alkynes, followed by methylation and transmetalation to Au(I) and Ir(III) complexes from the mesoionic carbene Ag(I) complexes. This methodology was applied to 6-azido penam and 7-azido cepham derivatives to build 6-(1,2,3-triazolyl)penam and 7-(1,2,3-triazolyl)cepham proligands, which upon methylation and metalation with Au(I) and Ir(III) complexes yielded products derived from the coordination of the metal to the penam C6 and cepham C7 positions, preserving intact the bicyclic structure of the penicillin and cephalosporin scaffolds. The crystal structure of complex 28b, which has an Ir atom directly bonded to the intact penicillin bicycle, was determined by X-ray diffraction. This is the first structural report of a penicillin-transition-metal complex having the bicyclic system of these antibiotics intact. The selectivity of the coordination processes was interpreted using DFT calculations.


Sujet(s)
Antibactériens , Céphalosporines , Complexes de coordination , Antibactériens/composition chimique , Antibactériens/synthèse chimique , Céphalosporines/composition chimique , Céphalosporines/synthèse chimique , Complexes de coordination/composition chimique , Complexes de coordination/synthèse chimique , Pénicillines/composition chimique , Pénicillines/synthèse chimique , Structure moléculaire , Modèles moléculaires , bêta-Lactames/composition chimique , bêta-Lactames/synthèse chimique ,
13.
Food Chem Toxicol ; 190: 114795, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38851521

RÉSUMÉ

Porcine thyroglobulin was important in the discovery of alpha-Gal allergy. Here, the linkage of porcine thyroglobulin-specific IgE with IgE positivity to routinely assessed allergens and to the incoming diagnosis within a population of suspected atopic individuals is explored. IgE, IgA, total IgG and IgG subclasses to porcine thyroglobulin, IgE to bovine, human thyroglobulin and meat extract were measured with ELISA. The following correlations were observed in IgE binding to porcine and bovine thyroglobulin (r = 0.910, p = 1x10-17), porcine and human thyroglobulin (r = 0.635, p = 4x10-6), human and bovine thyroglobulin (r = 0.746, p = 6x10-9) and porcine thyroglobulin and meat extract (r = 0.482, p = 0.0009). Only one out of ten samples which showed binding to porcine thyroglobulin in ELISA tested positive with ImmunoCAP alpha-Gal, implying different epitope/s. Increased IgE binding was detected towards a more electronegative fraction of porcine thyroglobulin separated according to charge and the binding could be partially inhibited by galactose. Anti-thyroglobulin IgE was found in 29.7% of the population, in subjects who were significantly younger, p < 0.0001 and it occurred more frequently in patients referred for testing penicillin specific IgE (OR 2.48, p = 0.0059) and were negative. IgE specific to porcine, bovine and possibly human thyroglobulin may be implicated in post-infectious skin manifestation misinterpreted as penicillin allergy.


Sujet(s)
Immunoglobuline E , Pénicillines , Thyroglobuline , Immunoglobuline E/immunologie , Thyroglobuline/immunologie , Animaux , Humains , Suidae , Adulte , Femelle , Adulte d'âge moyen , Bovins , Mâle , Pénicillines/effets indésirables , Études transversales , Adolescent , Jeune adulte , Hypersensibilité médicamenteuse/immunologie , Sujet âgé , Test ELISA , Allergènes/immunologie , Enfant
14.
Sci Total Environ ; 946: 174236, 2024 Oct 10.
Article de Anglais | MEDLINE | ID: mdl-38942308

RÉSUMÉ

Since the discovery of antibiotics, penicillin has remained the top choice in clinical medicine. With continuous advancements in biotechnology, penicillin production has become cost-effective and efficient. Genetic engineering techniques have been employed to enhance biosynthetic pathways, leading to the production of new penicillin derivatives with improved properties and increased efficacy against antibiotic-resistant pathogens. Advances in bioreactor design, media formulation, and process optimization have contributed to higher yields, reduced production costs, and increased penicillin accessibility. While biotechnological advances have clearly benefited the global production of this life-saving drug, they have also created challenges in terms of waste management. Production fermentation broths from industries contain residual antibiotics, by-products, and other contaminants that pose direct environmental threats, while increased global consumption intensifies the risk of antimicrobial resistance in both the environment and living organisms. The current geographical and spatial distribution of antibiotic and penicillin consumption dramatically reveals a worldwide threat. These challenges are being addressed through the development of novel waste management techniques. Efforts are aimed at both upstream and downstream processing of antibiotic and penicillin production to minimize costs and improve yield efficiency while lowering the overall environmental impact. Yield optimization using artificial intelligence (AI), along with biological and chemical treatment of waste, is also being explored to reduce adverse impacts. The implementation of strict regulatory frameworks and guidelines is also essential to ensure proper management and disposal of penicillin production waste. This review is novel because it explores the key remaining challenges in antibiotic development, the scope of machine learning tools such as Quantitative Structure-Activity Relationship (QSAR) in modern biotechnology-driven production, improved waste management for antibiotics, discovering alternative path to reducing antibiotic use in agriculture through alternative meat production, addressing current practices, and offering effective recommendations.


Sujet(s)
Antibactériens , Biotechnologie , Pénicillines , Biotechnologie/méthodes , Gestion des déchets/méthodes
15.
Anaesthesiologie ; 73(7): 436-443, 2024 Jul.
Article de Allemand | MEDLINE | ID: mdl-38904675

RÉSUMÉ

The beta-lactam antibiotics are some of the safest and best-tolerated antibiotic agents; however, many patients have reported allergies against penicillin. All beta-lactam antibiotics are only restrictively prescribed for these patients and alternative antibiotics are increasingly given, which carries the risk of negative clinical results and socioeconomic sequelae; however, over 95% of patients who reported an allergy to penicillin show a negative result in the allergy tests for penicillin and this antibiotic can safely be prescribed. The use of sensitive and specific instruments for identification of false penicillin allergies should be an important topic within the framework of antibiotic stewardship. Anesthesists can play a central role in the reduction of the enormous individual and public health burden associated with the classification of penicillin allergy by taking an appropriate medical history and a risk stratification for the identification of patients with a penicillin allergy. This overview article presents a possible delabelling algorithm within the framework of the clarification of a beta-lactam antibiotic allergy. The focus is on a structured allergy anamnesis using the penicillin allergy, five or fewer years ago, anaphylaxis/angioedema, severe cutaneous adverse reaction (SCAR) and treatment required for allergy episode (PEN-FAST) score.


Sujet(s)
Antibactériens , Hypersensibilité médicamenteuse , Pénicillines , Hypersensibilité médicamenteuse/diagnostic , Humains , Pénicillines/effets indésirables , Antibactériens/effets indésirables , Anaphylaxie/diagnostic , Algorithmes
16.
Clin Ther ; 46(6): 463-468, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38942719

RÉSUMÉ

PURPOSE: Penicillin allergy is the most common drug allergy among hospitalized patients. Traditionally, aztreonam is recommended for patients labeled with penicillin allergy (PLWPA) in our institutional empirical antibiotic guidelines. Due to a global aztreonam shortage in December 2022, the antimicrobial stewardship unit recommended ceftazidime as a substitute. There is a paucity of real-world data on the safety profile of ceftazidime in PLWPA. Hence, we evaluated tolerability outcomes of ceftazidime use in PLWPA. METHODS: This retrospective cohort study compared PLWPA in Singapore General Hospital who received aztreonam (October 2022-December 2022) or ceftazidime (December 2022-February 2023). Patients were stratified according to their risk of allergic reaction (AR) based on history of penicillin allergy. The severity of AR was based on the Delphi study grading system. The primary outcome was development of AR after initiation of aztreonam or ceftazidime. The secondary tolerability outcomes include hepatotoxicity and neurotoxicity. FINDINGS: There were 168 patients in the study; 69 were men (41.1%) and the median age was 69 years (interquartile range: 59-76 years). Incidence of AR was statistically similar in both arms: 1 of 102 patients (0.98%) in the aztreonam arm vs 2 of 66 patients (3.03%) in the ceftazidime arm (P = 0.33). The patient in the aztreonam arm was deemed at medium risk of having an AR and developed localized rashes (grade 1). Both patients in the ceftazidime arm were deemed at high risk of AR and developed localized skin reaction (grade 1). Hepatotoxicity was observed in 1 patient prescribed aztreonam. No patients in the ceftazidime arm developed adverse events. IMPLICATIONS: Ceftazidime appears to be better tolerated and cheaper compared with aztreonam in PLWPA, and serves as an antimicrobial stewardship strategy to conserve broader-spectrum antibiotics use.


Sujet(s)
Antibactériens , Aztréonam , Ceftazidime , Hypersensibilité médicamenteuse , Pénicillines , Humains , Aztréonam/effets indésirables , Aztréonam/administration et posologie , Ceftazidime/effets indésirables , Ceftazidime/usage thérapeutique , Ceftazidime/administration et posologie , Mâle , Hypersensibilité médicamenteuse/épidémiologie , Hypersensibilité médicamenteuse/étiologie , Adulte d'âge moyen , Femelle , Études rétrospectives , Sujet âgé , Antibactériens/effets indésirables , Antibactériens/administration et posologie , Pénicillines/effets indésirables , Études de cohortes , Singapour
17.
Clin Rev Allergy Immunol ; 66(2): 223-240, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38696031

RÉSUMÉ

Secondary prevention with penicillin aims to prevent further episodes of acute rheumatic fever and subsequent development of rheumatic heart disease (RHD). Penicillin allergy, self-reported by 10% of the population, can affect secondary prevention programs. We aimed to assess the role for (i) routine penicillin allergy testing and the (ii) safety of penicillin allergy delabeling approaches in this context. We searched MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, WHO ICTRP, ISRCTN, and CPCI-S to identify the relevant reports. We found 2419 records, but no studies addressed our initial question. Following advice from the WHO-Guideline committee and experts, we identified 6 manuscripts on allergy testing focusing on other populations showing that the prevalence of allergy confirmed by testing was low and the incidence of life-threatening reactions to BPG was very low (< 1-3/1000 individuals treated). A subsequent search addressed penicillin allergy delabeling. This found 516 records, and 5 studies addressing the safety of direct oral drug challenge vs. skin testing followed by drug administration in patients with suspected penicillin allergy. Immediate allergic reactions of minor severity were observed for a minority of patients and occurred less frequently in the direct drug challenge group: 2.3% vs. 11.5%; RR = 0.25, 95%CI 0.15-0.45, P < 0.00001, I2 = 0%. No anaphylaxis or deaths were observed. Severe allergic reactions to penicillin are extremely rare and can be recognized and dealt by trained healthcare workers. Confirmation of penicillin allergy diagnosis or delabeling using direct oral drug challenge or penicillin skin testing seems to be safe and is associated with a low rate of adverse reactions.


Sujet(s)
Hypersensibilité médicamenteuse , Pénicillines , Guides de bonnes pratiques cliniques comme sujet , Tests cutanés , Organisation mondiale de la santé , Humains , Hypersensibilité médicamenteuse/diagnostic , Hypersensibilité médicamenteuse/épidémiologie , Pénicillines/effets indésirables , Antibactériens/effets indésirables
18.
Adv Appl Microbiol ; 127: 143-221, 2024.
Article de Anglais | MEDLINE | ID: mdl-38763527

RÉSUMÉ

Almost one century after the Sir Alexander Fleming's fortuitous discovery of penicillin and the identification of the fungal producer as Penicillium notatum, later Penicillium chrysogenum (currently reidentified as Penicillium rubens), the molecular mechanisms behind the massive production of penicillin titers by industrial strains could be considered almost fully characterized. However, this filamentous fungus is not only circumscribed to penicillin, and instead, it seems to be full of surprises, thereby producing important metabolites and providing expanded biotechnological applications. This review, in addition to summarizing the classical role of P. chrysogenum as penicillin producer, highlights its ability to generate an array of additional bioactive secondary metabolites and enzymes, together with the use of this microorganism in relevant biotechnological processes, such as bioremediation, biocontrol, production of bioactive nanoparticles and compounds with pharmaceutical interest, revalorization of agricultural and food-derived wastes or the enhancement of food industrial processes and the agricultural production.


Sujet(s)
Pénicillines , Penicillium chrysogenum , Penicillium chrysogenum/métabolisme , Penicillium chrysogenum/génétique , Pénicillines/biosynthèse , Pénicillines/métabolisme , Biotechnologie , Dépollution biologique de l'environnement , Métabolisme secondaire , Microbiologie industrielle
19.
J Allergy Clin Immunol Pract ; 12(5): 1095-1106, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38724164

RÉSUMÉ

Risk stratification in drug allergy implies that specific risk categories (eg, low, moderate, and high) classify historical drug hypersensitivity reactions. These risk categories can be based on reaction phenotypic characteristics, the timing of the reaction and evaluation, the required reaction management, and individual characteristics. Although a multitude of frameworks have been described in the literature, particularly for penicillin allergy labels, there has yet to be a global consensus, and approaches continue to vary between allergy centers. Immune-mediated drug allergies can sometimes be confirmed using skin testing, but a negative drug challenge is required to demonstrate tolerance and remove the allergy from the electronic health record ("delabel" the allergy). Even for quintessential IgE-mediated drug allergy, penicillin allergy, recent data reveal that a direct oral challenge, without prior skin testing, is an appropriate diagnostic strategy in those who are considered low-risk. Drug allergy pathogenesis and clinical manifestations may vary depending on the culprit drug, and as such, the optimal approach should be based on risk stratification that considers individual patient and reaction characteristics, the likely hypersensitivity reaction phenotype, the drug class, and the patient's clinical needs. This article will describe low-risk drug allergy labels, focusing on ß-lactam and sulfonamide antibiotics, nonsteroidal anti-inflammatory drugs, iodinated contrast media, and common chemotherapeutics. This review will also address practical management approaches using currently available risk stratification and clinical decision tools.


Sujet(s)
Hypersensibilité médicamenteuse , Humains , Hypersensibilité médicamenteuse/diagnostic , Hypersensibilité médicamenteuse/thérapie , Tests cutanés , Appréciation des risques , Pénicillines/effets indésirables , Pénicillines/immunologie , Immunoglobuline E , Antibactériens/effets indésirables , Antibactériens/immunologie
20.
J Med Chem ; 67(11): 9613-9627, 2024 Jun 13.
Article de Anglais | MEDLINE | ID: mdl-38776401

RÉSUMÉ

The development of antibacterial drugs with new mechanisms of action is crucial in combating the rise of antibiotic-resistant infections. Bacterial carbonic anhydrases (CAs, EC 4.2.1.1) have been validated as promising antibacterial targets against pathogens such as Helicobacter pylori, Neisseria gonorrhoeae, and vancomycin-resistant enterococci. A multitarget strategy is proposed to design penicillin-based CA inhibitor hybrids for tackling resistance by targeting multiple bacterial pathways, thereby resensitizing drug-resistant strains to clinical antibiotics. The sulfonamide derivatives potently inhibited the CAs from N. gonorrhoeae and Escherichia coli with KI values in the range of 7.1-617.2 nM. Computational simulations with the main penicillin-binding protein (PBP) of N. gonorrhoeae indicated that these hybrid derivatives maintained the mechanism of action of the lead ß-lactams. A subset of derivatives showed potent PBP-related antigonococcal effects against multidrug-resistant N. gonorrhoeae strains, with several compounds significantly outperforming both the lead ß-lactam and CA inhibitor drugs (MIC values in the range 0.25 to 0.5 µg/mL).


Sujet(s)
Antibactériens , Inhibiteurs de l'anhydrase carbonique , Carbonic anhydrases , Tests de sensibilité microbienne , Neisseria gonorrhoeae , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Neisseria gonorrhoeae/enzymologie , Inhibiteurs de l'anhydrase carbonique/pharmacologie , Inhibiteurs de l'anhydrase carbonique/composition chimique , Inhibiteurs de l'anhydrase carbonique/synthèse chimique , Antibactériens/pharmacologie , Antibactériens/composition chimique , Antibactériens/synthèse chimique , Carbonic anhydrases/métabolisme , Pénicillines/pharmacologie , Pénicillines/composition chimique , Multirésistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Relation structure-activité , Humains , Sulfonamides/pharmacologie , Sulfonamides/composition chimique , Sulfonamides/synthèse chimique , Structure moléculaire , Escherichia coli/effets des médicaments et des substances chimiques , Escherichia coli/enzymologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE